---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-279021"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:56:31.578026+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial

## Summary
- Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.
- Diplopia response 56% vs 25% (p=0.0006); complete resolution 32% vs 14% (p=0.0152) in chronic patients.
- 54% of veligrotug patients achieved CAS 0 or 1 vs 24% placebo (p=0.006); overall responder rate 56% vs 7%.
- Veligrotug well-tolerated; 94% completed treatment; 9.6% placebo-adjusted rate of hearing impairment.
- BLA submission on track for H2 2025; $753M cash on hand provides runway into H2 2027.

## SEC filing metadata
- accession: 0001193125-24-279021
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/0001193125-24-279021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-279021
- JSON: https://secwatch.observer/filing/0001193125-24-279021.json
- Plain text: https://secwatch.observer/filing/0001193125-24-279021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.